1
|
Campos DMO, Silva MK, Morais GCF, Neto JFR, Oliveira JIN. Brief Overview of Clinical Evidence for Homeopathic Interventions in the Management of COVID-19 Patients. HOMEOPATHY 2024; 113:126-130. [PMID: 37918827 DOI: 10.1055/s-0043-1771375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2023]
Affiliation(s)
- Daniel M O Campos
- Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande do Norte, 59064-741, Natal/RN, Brazil
| | - Maria K Silva
- Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande do Norte, 59064-741, Natal/RN, Brazil
| | - Gabriel C F Morais
- Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande do Norte, 59064-741, Natal/RN, Brazil
| | - João F R Neto
- Multicampi School of Medical Sciences, Federal University of Rio Grande do Norte, 59300-000, Caicó/RN, Brazil
| | - Jonas I N Oliveira
- Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande do Norte, 59064-741, Natal/RN, Brazil
| |
Collapse
|
2
|
Saxena SK, Kumar S, Maurya VK, Nayak D, Kaushik S, Manchanda RK, Gadugu S. Antiviral and anti-inflammatory activity of novel belladonna formulation against Japanese encephalitis virus via inhibition of p65 nuclear translocation and TNF-α mediated NF-kB signaling. Biotechnol Genet Eng Rev 2023:1-23. [PMID: 36718919 DOI: 10.1080/02648725.2023.2166258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 12/31/2022] [Indexed: 02/01/2023]
Abstract
Japanese encephalitis (JE) is a mosquito-borne flavivirus infection, a major cause of viral encephalitis in South-East Asia with a CFR of ~30% and no specific treatment. Therefore, a novel belladonna formulation (BCT) was prepared and its antiviral and anti-inflammatory activity was elucidated during Japanese encephalitis virus (JEV) infection. Anti-JEV role of BCT was investigated aiming to prevent the infection in the peripheral immune cells. Antiviral activity of BCT was evaluated by plaque reduction assay, cell survival and apoptosis assay. BCT-mediated reduction in JEV-envelope expression was measured by indirect immunofluorescence, RT-PCR and Western blot assays. NF-κB expression and p65 nuclear translocation assays were determined to explore the mechanism of the action of BCT. TNF-α level was measured to evaluate the anti-inflammatory role of BCT during JEV infection. Consequently, molecular docking was performed with the TRAF2-TRADD complex. Our data suggested that BCT treatment reduces the JEV-plaque formation, JEV-induced cytopathic effects and increases cell survival. The antiviral effect of BCT was confirmed by reduction in the JEV-envelope protein expression. Moreover, BCT treatment and prevents the NF-κB activation via preventing the nuclear translocation of p65 and reduces the TNF-α levels. Our molecular docking analysis suggested that belladonna alkaloids interfere with the TRAF2-TRADD complex that results in inhibition of TNF-induced NF-κB signaling. For the first time, our data suggested that BCT reduces JEV expression and interferes with TNF-induced NF-κB signaling, thereby increasing cell survival via preventing the p65 nuclear translocation and may be used for the treatment and prevention of JE.Abbreviation: CFR: Case fatality rate; CAM: Complementary and alternative medicines; COX-2: Cyclooxygenase-2; IκB: Inhibitor kappa B; JE: Japanese encephalitis; JEV: Japanese encephalitis virus; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; ORF: Open reading frame; TNFR: Tumor necrosis factor receptor; TNF-α: Tumor necrosis factor-α; TRADD: TNFR1-associated death domain protein; TRAF2: TNF Receptor Associated Factor 2.
Collapse
Affiliation(s)
- Shailendra K Saxena
- Centre for Advanced Research, Faculty of Medicine, King George's Medical University, Lucknow, India
| | - Swatantra Kumar
- Centre for Advanced Research, Faculty of Medicine, King George's Medical University, Lucknow, India
| | - Vimal K Maurya
- Centre for Advanced Research, Faculty of Medicine, King George's Medical University, Lucknow, India
| | | | | | | | - Srinivasulu Gadugu
- Department of Medicine, JSPS Government Medical College, Hyderabad, India
| |
Collapse
|
3
|
Varanasi R, Tomar S, Gupta S, Jaiswal P, Srivastava A, Parmar V, Chauhan S, Kumar A, Mishra SK, Khurana A. Comparative Effectiveness of Pre-Identified Homeopathic Medicines in Asymptomatic COVID-19 Individuals Receiving Standard Care-An Open-Label, Randomized, Controlled Exploratory Trial. HOMEOPATHY 2022; 111:252-260. [PMID: 35917822 DOI: 10.1055/s-0042-1745754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND AND OBJECTIVES Asymptomatic COVID-19 subjects can transmit the infection for as many as 14 days and are regarded as a significant factor in the rapid spread of the COVID-19 pandemic. This exploratory study aimed to determine any additional benefits of selected homeopathic medicines compared with placebo in asymptomatic COVID-19 individuals receiving standard care. METHODS This open-label, randomized, placebo-controlled, exploratory trial was undertaken at a COVID Care Centre (CCC) in Madhya Pradesh, India. Patients (n = 200, 18-65 years, both sexes) having a positive RT-PCR and asymptomatic during admission were enrolled. They were randomly assigned to one of four groups (each n = 50): Arsenicum album 30C (Ars. alb.), Camphora 1M (Camph.), Bryonia alba 30C (Bry. alb.) and placebo (Pl.). All the patients were given standard care. The primary outcome was the number of patients becoming RT-PCR negative for SARS-CoV-2 at days 5, 10 and 15. RESULTS In total, 200 asymptomatic COVID-19 patients were enrolled. One hundred and seventy-seven patients became RT-PCR negative by day 15; 88%, 80%, 98% and 88% from Ars. alb., Camph., Bry. alb. and Pl. respectively. A Chi-square test of association for the total patients who became RT-PCR negative for SARS-Cov-2 in each group showed a marginal statistical significance (Chi-square: 8.1, p = 0.04). A two-proportion Z-test comparing each pre-identified homeopathic medicine with placebo showed marginal statistical significance (p = 0.05) for Bry alb. only. Median time in days to RT-PCR negative (Kaplan Meier analysis) was 10 days in each of the groups. CONCLUSION There was some evidence that, compared with Ars alb., Camph. or Pl., Bry. alb. was associated with an increased number of patients who became RT-PCR negative for COVID-19 by day 15. The possible effect exerted needs to be investigated in additional research.
Collapse
Affiliation(s)
- Roja Varanasi
- Department of Clinical Research, Central Council for Research in Homoeopathy (CCRH), New Delhi, India
| | - Sunita Tomar
- Department of Pathology, Government Homeopathic Medical College and Hospital (GHMC), Bhopal, Madhya Pradesh, India
| | - Sanjay Gupta
- Department of Practice of Medicine, GHMC, Bhopal, Madhya Pradesh, India
| | - Praveen Jaiswal
- Department of Practice of Medicine, GHMC, Bhopal, Madhya Pradesh, India
| | - Ankit Srivastava
- Department of Materia Medica, GHMC, Bhopal, Madhya Pradesh, India
| | - Vijendra Parmar
- Department of Orthopedics, Gandhi Medical College, Bhopal, Madhya Pradesh, India
| | | | - Arvind Kumar
- Department of Biostatistics, CCRH, New Delhi, India
| | | | - Anil Khurana
- Department of Clinical Research, Central Council for Research in Homoeopathy (CCRH), New Delhi, India
| |
Collapse
|
4
|
Nayak D, Gupta J, Chaudhary A, Singh KG, Deshmukh A, Das D, Saha A, Kumar D, Kumar A, Goenka A, Mishra S, Gupta S, Khurana A. Efficacy of individualized homeopathy as an adjunct to standard of care of COVID-19: A randomized, single-blind, placebo-controlled study. Complement Ther Clin Pract 2022; 48:101602. [PMID: 35569230 PMCID: PMC9080028 DOI: 10.1016/j.ctcp.2022.101602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 05/05/2022] [Accepted: 05/05/2022] [Indexed: 01/27/2023]
Affiliation(s)
- Debadatta Nayak
- Epidemic Cell, Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi, 110058, India,Corresponding author
| | - Juhi Gupta
- Dept. of Physiology, Government Homoeopathic Medical College and Hospital, AYUSH Campus, MACT Hills, Kaliasot Dam Approach Rd, Chuna Bhatti, Bhopal, Madhya Pradesh, 462003, India
| | - Anupriya Chaudhary
- Dept. of Clinical Research, Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi, 110058, India
| | - Krishna Gopal Singh
- Dept. of Pulmonary Medicine, Chirayu Medical College & Hospital. Bhopal-Indore Highway Bhainsakhedi, Bairagarh, Bhopal, Madhya Pradesh, 462030, India
| | - Abhijeet Deshmukh
- Dept. of Surgery, Chirayu Medical College & Hospital, Bhopal-Indore Highway Bhainsakhedi, Bairagarh, Bhopal, Madhya Pradesh, 462030, India
| | - Deblina Das
- Epidemic Cell, Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi, 110058, India
| | - Abhishek Saha
- Intermediary Pharmacovigilance Centre (Homoeopathy), National Institute of Homoeopathy, GE Block, Sector-III, Salt Lake, Kolkata, 700106, India
| | - Deepak Kumar
- Epidemic Cell, Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi, 110058, India
| | - Ashwini Kumar
- Epidemic Cell, Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi, 110058, India
| | - Ajay Goenka
- Chirayu Medical College & Hospital, Bhopal-Indore Highway Bhainsakhedi, Bairagarh, Bhopal, Madhya Pradesh, 462030, India
| | - S.K. Mishra
- Government Homoeopathic Medical College and Hospital, AYUSH Campus, MACT Hills, Kaliasot Dam Approach Rd, Chuna Bhatti, Bhopal, Madhya Pradesh, 462003, India
| | - Sanjay Gupta
- Dept. of Practice of Medicine, Government Homoeopathic Medical College and Hospital, AYUSH Campus, MACT Hills, Kaliasot Dam Approach Rd, Chuna Bhatti, Bhopal, Madhya Pradesh, 462003, India
| | - Anil Khurana
- Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi, 110058, India
| |
Collapse
|
5
|
Manchanda RK, Miglani A, Gupta M, Meena BS, Chadha V, Joseph F, Kalsi A, Konthembath P, Sharma K, Rama KN, Kaur P, Thavarayil Kannoth J, Nagrath C, Jethani A, Nellikka Aniyeri S, Chawla A, Ray MK, Ghuliani M, Kudiyarasu RK, Naskar S, Bala S, Sharma B. Homeopathic Remedies in COVID-19: Prognostic Factor Research. HOMEOPATHY 2021; 110:160-167. [PMID: 33930904 DOI: 10.1055/s-0041-1725989] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND/OBJECTIVE Coronavirus disease 2019 (COVID-19) is a new disease; its clinical profile and natural history are evolving. Each well-recorded case in homeopathic practice is important for deciding the future course of action. This study aims at identifying clinically useful homeopathic remedies and their prescribing symptoms using the prognostic factor research model. METHODS This was an open-label, multi-centric, observational study performed from April 2020 to July 2020 at various public health care clinics. The data were collected prospectively from clinical practice at integrated COVID-19 care facilities in India. Good-quality cases were selected using a specific set of criteria. These cases were analyzed for elucidating prognostic factors by calculating the likelihood ratio (LR) of each frequently occurring symptom. The symptoms with high LR values (>1) were considered as prescribing indications of the specific remedy. RESULTS Out of 327 COVID-19 cases reported, 211 met the selection criteria for analysis. The most common complaints were fatigue, sore throat, dry cough, myalgia, fever, dry mouth and throat, increased thirst, headache, decreased appetite, anxiety, and altered taste. Twenty-seven remedies were prescribed and four of them-Arsenicum album, Bryonia alba, Gelsemium sempervirens, and Pulsatilla nigricans-were the most frequently used. A high LR was obtained for certain symptoms, which enabled differentiation between the remedies for a given patient. CONCLUSION Homeopathic medicines were associated with improvement in symptoms of COVID-19 cases. Characteristic symptoms of four frequently indicated remedies have been identified using prognostic factor research, findings that can contribute to accurate homeopathic prescribing during future controlled research in COVID-19.
Collapse
Affiliation(s)
- Raj Kumar Manchanda
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Anjali Miglani
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Meeta Gupta
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Baljeet Singh Meena
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Vishal Chadha
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Franco Joseph
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Amrit Kalsi
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Pramod Konthembath
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Kavita Sharma
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Kamsali Nadigadda Rama
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Prabhjeet Kaur
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Jithesh Thavarayil Kannoth
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Cheshta Nagrath
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Anju Jethani
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Shajimol Nellikka Aniyeri
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Anu Chawla
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Malaya Kumar Ray
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Manjula Ghuliani
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Ram Kumar Kudiyarasu
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Shruti Naskar
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Sudha Bala
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| | - Brender Sharma
- Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India
| |
Collapse
|
6
|
Varanasi R, Nayak D, Khurana A. Clinical Repurposing of Medicines is Intrinsic to Homeopathy: Research Initiatives on COVID-19 in India. HOMEOPATHY 2021; 110:198-205. [PMID: 33853178 DOI: 10.1055/s-0041-1725988] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
As at mid-October 2020, the coronavirus disease 2019 (COVID-19) pandemic has been continuing on the rise across the globe, including in India. Historically, homeopathy has been used in a number of epidemics/pandemics. The development of homeopathic medicines is approached uniquely through "drug provings" and clinical verification; these two intrinsic processes establish the background for the application of homeopathic medicines, regardless of nosological diagnosis. This article reflects research initiatives on COVID-19 in India and identifies studies listed in the Clinical Trial Registry-India database. We identified 29 studies being undertaken in different settings, including those in conventional medicine: 20 randomized controlled trials (RCTs) and 9 observational studies. Fifteen studies are aimed at prophylaxis and 14 are aimed at treatment. Amongst the treatment studies, 11 are focused on efficacy or comparative effectiveness. The findings might provide evidence for clinically repurposing some of homeopathy's medicines, an approach that is intrinsic to the therapy, enabling their use in COVID-19 as an adjuvant or stand-alone to help reduce costs and improve patient recovery.
Collapse
Affiliation(s)
- Roja Varanasi
- Central Council for Research in Homoeopathy, New Delhi, India
| | - Debadatta Nayak
- Central Council for Research in Homoeopathy, New Delhi, India
| | - Anil Khurana
- Central Council for Research in Homoeopathy, New Delhi, India
| |
Collapse
|
7
|
Jethani B, Gupta M, Wadhwani P, Thomas R, Balakrishnan T, Mathew G, Mathur M, Rao BP, Shukla D, Khullar A, Khera M, Sharma H, Kumar R, Kumar S, Jaggi S, Sinha R, Rawal K, Kapoor A, Manchanda RK. Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study. HOMEOPATHY 2021; 110:86-93. [PMID: 33567460 DOI: 10.1055/s-0040-1718584] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVE The aim of the study was to identify indicated homeopathic remedies based on the clinical characteristics of coronavirus disease 2019 (COVID-19) patients in India. METHODS In this retrospective, cohort study, confirmed COVID-19 patients admitted at a COVID Health Centre in New Delhi between April 29 and June 17, 2020 were given conventional and homeopathic treatment. Patients were grouped into mild, moderate or severe categories of disease. Their symptomatologic profiles were analyzed to identify indicated homeopathic medicines. RESULTS A total of 196 COVID-19 patients were admitted. One hundred and seventy-eight patients had mild symptoms; eighteen patients had moderate symptoms; no patients with severe symptoms were included as they were referred to tertiary care centers with ventilatory support. The mean age of patients with mild symptoms was significantly lower (38.6 years; standard deviation or SD ± 15.8) compared with patients in the moderate category (66.0 years; SD ± 9.09). The most important symptoms identified were fever (43.4%), cough (47.4%), sore throat (29.6%), headache (18.4%), myalgia (17.9%), fatigue (16.8%), chest discomfort (13.8%), chills (12.6%), shortness of breath (11.2%) and loss of taste (10.2%). Twenty-eight homeopathic medicines were prescribed, the most frequently indicated being Bryonia alba (33.3%), Arsenicum album (18.1%), Pulsatilla nigricans (13.8%), Nux vomica (8%), Rhus toxicodendron (7.2%) and Gelsemium sempervirens (5.8%), in 30C potency. CONCLUSION Data from the current study reveal that Arsenicum album, Bryonia alba, Pulsatilla nigricans, Nux vomica, Rhus toxicodendron and Gelsemium sempervirens are the most frequently indicated homeopathic medicines. A randomized controlled clinical trial based on this finding is the next step.
Collapse
Affiliation(s)
- Bipin Jethani
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | | | - Parul Wadhwani
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Rekha Thomas
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | | | - George Mathew
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Mohit Mathur
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | | | - Dhananjay Shukla
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Aashima Khullar
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Meghna Khera
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Himani Sharma
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Ravinder Kumar
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Sudeep Kumar
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Sayami Jaggi
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Robin Sinha
- Center for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India
| | - Kamal Rawal
- Center for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India
| | - Anu Kapoor
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| | - Raj Kumar Manchanda
- Nehru Homoeopathic Medical College and Hospital, Defence Colony, New Delhi, India
| |
Collapse
|
8
|
Talwar S, Sood S, Kumar J, Chauhan R, Sharma M, Tuli HS. Ayurveda and Allopathic Therapeutic Strategies in Coronavirus Pandemic Treatment 2020. ACTA ACUST UNITED AC 2020; 6:354-363. [PMID: 33106765 PMCID: PMC7577842 DOI: 10.1007/s40495-020-00245-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/06/2020] [Indexed: 12/20/2022]
Abstract
Purpose of Review In the last month of 2019, i.e., December, COVID-19 hit Wuhan city in China. Since then, it has infected more than 210 countries and nearly about 33.4 million people with one million deaths globally. It is a viral disease with flu-like symptoms; hence, prevention and management is the best option to be adopted for its cure. Recent Findings Many healthcare systems, scientists, and researchers are fighting for the cure of this pandemic. Ayurvedic and allopathic treatments have been studied extensively and approached for the cure of COVID-19. In addition to ayurvedic treatments, the Ministry of Ayush, India, has also recommended many remedies to boost up immunity. Allopathic studies involved several antiviral drugs which were used in different combinations for the treatment of COVID-19. Summary Comparative analysis of Ayurveda and allopathic treatment strategies were carried out in the present study. Depending upon the patient’s conditions and symptoms, Ayurveda is useful for the treatment of COVID-19. Allopathic treatments inhibit viral infection by targeting majorly endocytosis, and angiotensin-converting enzyme (Ace) receptor signaling. In this article, we summarize different ayurvedic and allopathic medicines and treatment strategies which have been used for the treatment of COVID-19, a global pandemic.
Collapse
Affiliation(s)
- Shivangi Talwar
- Amity Institute of Biotechnology, Amity University, Noida, Noida, India
| | - Shivani Sood
- Department of Biotechnology, Mukand Lal National College, Yamuna Nagar, India
| | - Jayant Kumar
- Department of Biotechnology, Mukand Lal National College, Yamuna Nagar, India
| | - Ritu Chauhan
- Amity Institute of Biotechnology, Amity University, Noida, Noida, India
| | - Mamta Sharma
- School of Law, Justice and Governance, Gautam Buddha University, Greater Noida, India
| | - Hardeep Singh Tuli
- Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, 133207 India
| |
Collapse
|
9
|
Maurya VK, Kumar S, Kabir R, Shrivastava G, Shanker K, Nayak D, Khurana A, Manchanda RK, Gadugu S, Kar SK, Verma AK, Saxena SK. Dark Classics in Chemical Neuroscience: An Evidence-Based Systematic Review of Belladonna. ACS Chem Neurosci 2020; 11:3937-3954. [PMID: 32662978 DOI: 10.1021/acschemneuro.0c00413] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Belladonna has diverse pharmacotherapeutic properties with a shadowy history of beauty, life, and death. Alkaloids present in belladonna have anti-inflammatory, anticholinergic, antispasmodic, mydriatic, analgesic, anticonvulsant, and antimicrobial activities, which makes it widely applicable for the treatment of various diseases. However, because of its associated toxicity, the medicinal use of belladonna is debatable. Therefore, an evidence-based systematic review was planned to elucidate the pharmacotherapeutic potential of belladonna. A comprehensive literature search was performed in PubMed, MEDLINE, the Cochrane database, Embase, and ClinicalTrials.gov using the keywords "belladonna", "belladonna and clinical trials", and "safety and efficacy of belladonna". Articles published from 1965 to 2020 showing the efficacy of belladonna in diverse clinical conditions are included. The quality of evidence was generated using the GRADE approach, and 20 studies involving 2302 patients were included for the systematic review. Our analyses suggest that belladonna treatment appears to be safe and effective in various disease conditions, including acute encephalitis syndrome, urethral stent pain, myocardial ischemia injury, airway obstructions during sleep in infants, climacteric complaints, irritable bowel syndrome, and throbbing headache. However, better understanding of the dosage and the toxicity of tropane alkaloids of belladonna could make it an efficient remedy for treating diverse medical conditions.
Collapse
Affiliation(s)
- Vimal K. Maurya
- Centre for Advanced Research, Faculty of Medicine, King George’s Medical University, Lucknow 226003, India
| | - Swatantra Kumar
- Centre for Advanced Research, Faculty of Medicine, King George’s Medical University, Lucknow 226003, India
| | - Russell Kabir
- School of Allied Health, Faculty of Health, Education, Medicine, and Social Care, Anglia Ruskin University, Chelmsford CM1 1SQ, United Kingdom
| | - Gaurav Shrivastava
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, United States
| | - Karuna Shanker
- CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow 226015, India
| | - Debadatta Nayak
- CCRH, Ministry of Ayush, Government of India, New Delhi 110058, India
| | - Anil Khurana
- CCRH, Ministry of Ayush, Government of India, New Delhi 110058, India
| | - Raj K Manchanda
- CCRH, Ministry of Ayush, Government of India, New Delhi 110058, India
| | - Srinivasulu Gadugu
- Department of Medicine, JSPS Government Medical College, Hyderabad 500013, India
| | - Sujita K. Kar
- Department of Psychiatry, King George’s Medical University, Lucknow 226003, India
| | - Anoop K. Verma
- Department of Forensic Medicine and Toxicology, King George’s Medical University, Lucknow 226003, India
| | - Shailendra K. Saxena
- Centre for Advanced Research, Faculty of Medicine, King George’s Medical University, Lucknow 226003, India
| |
Collapse
|
10
|
|
11
|
Taneja D, Khurana A. An online cross-sectional survey on knowledge, attitudes, practices and perspectives of homoeopathic practitioners towards COVID-19. INDIAN JOURNAL OF RESEARCH IN HOMOEOPATHY 2020. [DOI: 10.4103/ijrh.ijrh_35_20] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
12
|
Kaur H, Azis S. Enabling use of Homoeopathy in India's preparedness for pandemic/epidemic situation like COVID-19. INDIAN JOURNAL OF RESEARCH IN HOMOEOPATHY 2020. [DOI: 10.4103/ijrh.ijrh_42_20] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
13
|
To KA. Simplify the complexity and replicate the simplicity: Book review of Standard Treatment Guidelines in Homoeopathy. INDIAN JOURNAL OF RESEARCH IN HOMOEOPATHY 2020. [DOI: 10.4103/ijrh.ijrh_88_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
14
|
Varanasi R, Nayak D. Homoeopathy in the management of infectious diseases: Different facets of its use and implications for the future. INDIAN JOURNAL OF RESEARCH IN HOMOEOPATHY 2020. [DOI: 10.4103/ijrh.ijrh_40_20] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
15
|
Saxena SK, Kumar S, Maurya VK. Pathogen-associated acute encephalitis syndrome: therapeutics and management. Future Microbiol 2019; 14:259-262. [DOI: 10.2217/fmb-2018-0334] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Affiliation(s)
- Shailendra K Saxena
- Center for Advanced Research (CFAR) – Stem Cell/Cell Culture Unit, Faculty of Medicine, King George's Medical University (KGMU), Lucknow 226003, India
- CSIR – Center for Cellular & Molecular Biology, Uppal Road, Hyderabad 500007, India
| | - Swatantra Kumar
- Center for Advanced Research (CFAR) – Stem Cell/Cell Culture Unit, Faculty of Medicine, King George's Medical University (KGMU), Lucknow 226003, India
| | - Vimal K Maurya
- Center for Advanced Research (CFAR) – Stem Cell/Cell Culture Unit, Faculty of Medicine, King George's Medical University (KGMU), Lucknow 226003, India
| |
Collapse
|